Education
About Us
Working with TipRanks
Follow Us
Neovacs SA (FR:ALNEV)
:ALNEV
ALNEV Stock Chart & Stats
€0.22
-€0.06(-6.03%)
At close: 4:00 PM EST
€0.22
-€0.06(-6.03%)
Day’s Range― - ―
52-Week Range€0.03 - €3,150.00
Previous CloseN/A
Volume950.00
Average Volume (3M)888.10K
Market Cap
€19.07K
Enterprise ValueN/A
Total Cash (Recent Filing)€435.45K
Total Debt (Recent Filing)€230.37K
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Oct 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding476,625
10 Day Avg. Volume1,708,825
30 Day Avg. Volume888,098
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)9.86
Price to Sales (P/S)485.89
P/FCF Ratio-48.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€4.33K
Neovacs SA News
ALNEV FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €0.03 and its highest was €3150.00 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €19.07K.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Oct 23, 2025 which is 16 days ago.
How were Neovacs SA’s earnings last quarter?
Currently, no data Available
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 476,625 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in FR:ALNEV
Company Description
Neovacs SA
Neovacs SA (ALNEV) is a biotechnology company focused on developing immunotherapies for autoimmune diseases and allergic disorders. The company specializes in its proprietary platform technology, which utilizes a therapeutic vaccine approach to stimulate the immune system to produce specific antibodies. Neovacs is primarily engaged in the research and development of innovative treatments, targeting conditions such as lupus and other chronic inflammatory diseases.